← Leaderboards
Kevin W Garey
Baylor College Of Medicine
$4,468,317
Attributed
$13,530,045
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,530,045 · 4
By mechanism
U01$7,916,381 · 1
R44$2,911,659 · 1
R01$2,545,588 · 1
R03$156,417 · 1
Top collaborators
- Robert A Britton5 shared
- Julian G Hurdle5 shared
- Tor C. Savidge5 shared
- Joe Sorg5 shared
- Dimitrios Iliopoulos3 shared
- Zhiyong Yang3 shared
- Charalabos Pothoulakis2 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Robert A Britton$17,520,348
- Sharon Emma Plon$39,994,796
- Amy Lynn McGuire$13,971,446
- Donald W. Parsons$9,398,880
- Heather A. Danhof$190,922
Others in their field
Top investigators on “Recurrence”
- Philip J Disaia · University Of California Irvine$95,481,777
- David Heimbrook · Leidos Biomedical Research, Inc.$87,033,539
- Wafaa M. El-Sadr · Columbia University Health Sciences$84,793,830
- Myron S Cohen · Family Health International$84,793,830
- Lawrence Corey · Fred Hutchinson Cancer Center$59,594,035
- Dan H. Barouch · Fred Hutchinson Cancer Center$59,594,035
Research focus
RecurrenceClostridium DifficileInfectionAntibioticsAntibiotic ResistancePredispositionTreatment FailureResistancePublic HealthVancomycinHospitalsMolecularMetronidazole ResistanceMetronidazoleMetadataEpidemicAffectHigh RiskResponseEpidemiologyCessation Of LifeMicrobiomeBioreactorsBioinformatics
Grant awards (15)
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$744,973
R01 · FY2025 · AI
Vancomycin Susceptibility Measures to Evaluate C. difficile infection Outcomes$78,500
R03 · FY2025 · AI · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$768,082
R01 · FY2024 · AI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$183,766
R01 · FY2024 · AI
Vancomycin Susceptibility Measures to Evaluate C. difficile infection Outcomes$77,917
R03 · FY2024 · AI · contact PI
Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection$52,374
R01 · FY2024 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$923,175
R44 · FY2023 · AI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$796,393
R01 · FY2023 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$988,488
R44 · FY2022 · AI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$999,996
R44 · FY2021 · AI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,486,851
U01 · FY2020 · AI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,482,023
U01 · FY2019 · AI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,952,767
U01 · FY2018 · AI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,494,740
U01 · FY2017 · AI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,500,000
U01 · FY2016 · AI